MapLight Therapeutics reported financial results for the third quarter of 2025.
Topline results from Phase 2 trials for schizophrenia and Alzheimer's disease psychosis are expected in 2026 and 2027 respectively.
Raised $296.5 million in gross proceeds from IPO and private placement completed in October 2025.
Topline Trial Results Expected
Expecting Phase 2 ZEPHYR trial results for schizophrenia in 2026 and Phase 2 VISTA trial results for Alzheimer's disease psychosis in 2027.
Successful Fundraising
Raised $296.5 million in gross proceeds from IPO and private placement in October 2025.
Financial Stability
Current cash reserves and recent fundraising expected to fund operations through 2027.
- MapLight Therapeutics made significant progress in its clinical trials for CNS disorders.
- Successful fundraising provides financial stability for ongoing operations and research.
- Anticipated trial results in 2026 and 2027 could have a significant impact on the company's future direction.
With strong financial backing and promising clinical trial results on the horizon, MapLight Therapeutics is positioned for continued growth in the biopharmaceutical industry.